Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Eur J Cardiothorac Surg. 2013 Jul;44(1):e59-64. doi: 10.1093/ejcts/ezt195. Epub 2013 May 3.
The standard surgical treatment for patients with non-small-cell lung cancer (NSCLC) is lobectomy with systematic nodal dissection (SND). Lobe-specific patterns of nodal metastases have been recognized, and lobe-specific SND (L-SND) has been reported. We performed L-SND depending on patient-related factors, such as age or the presence of diabetes or respiratory dysfunction, or in the context of specific tumour-related factors, such as the presence of a tumour with a wide area of ground-glass opacity.
Between September 2002 and December 2008, 335 consecutive patients with clinical and intraoperative N0 NSCLC underwent curative lobectomies at Shizuoka Cancer Center Hospital. Among these 335 patients, 206 underwent SND (Group A) and 129 underwent L-SND. Of the 129 patients undergoing L-SND, 98 underwent L-SND due to patient-related factors (Group B) and 31 underwent L-SND due to tumour-related factors (Group C).
There were no significant differences in morbidity or blood loss between patients undergoing SND or L-SND, but there was a significant difference in the mean operative times. The 5-year disease-free survival (5-DFS) and 5-year overall survival (5-OS) of patients in Group C were 100%. Although the patients in Group B showed no significant difference in 5-DFS and 5-OS compared with Group A, patients in Group B had significantly more initial recurrence of mediastinal node cancer than did the Group A patients (P = 0.0050).
The recurrence of mediastinal node cancer in patients undergoing L-SND was significantly greater than that in those undergoing SND.
对于非小细胞肺癌(NSCLC)患者,标准的外科治疗方法是肺叶切除术伴系统性淋巴结清扫术(SND)。已经认识到肺叶特异性淋巴结转移模式,并且已经报道了肺叶特异性淋巴结清扫术(L-SND)。我们根据患者相关因素(如年龄、是否存在糖尿病或呼吸功能障碍)或特定肿瘤相关因素(如存在大面积磨玻璃密度肿瘤)进行 L-SND。
2002 年 9 月至 2008 年 12 月,335 例临床和术中 N0 NSCLC 患者在静冈癌症中心医院接受了根治性肺叶切除术。在这 335 例患者中,206 例行 SND(A 组),129 例行 L-SND。在接受 L-SND 的 129 例患者中,98 例由于患者相关因素(B 组),31 例由于肿瘤相关因素(C 组)接受了 L-SND。
接受 SND 或 L-SND 的患者在发病率或出血量方面没有差异,但手术时间有显著差异。C 组患者的 5 年无病生存率(5-DFS)和 5 年总生存率(5-OS)为 100%。虽然 B 组患者与 A 组患者相比,5-DFS 和 5-OS 无显著差异,但 B 组患者的纵隔淋巴结癌初始复发率显著高于 A 组患者(P=0.0050)。
接受 L-SND 的患者纵隔淋巴结癌的复发明显多于接受 SND 的患者。